Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.
Christian F. Singer(Medical University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Christine Brunner(Innsbruck Medical University), Richard Greil(Paracelsus Medical University), Yen Y. Tan(Comprehensive Cancer Center Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Daniel Reimer(Innsbruck Medical University), Annette Reiner(Innsbruck Medical University), Katharina Knoll(German Centre for Cardiovascular Research), Michael Seifert(Zimmer Biomet (Germany)), Edgar Petru(Medical University of Graz), Georg Pfeiler(Comprehensive Cancer Center Vienna), C Peters-Engl(Karl Landsteiner Society), Christoph Suppan(Medical University of Graz), Petra Pichler(Universitätsklinikum St. Pölten), Renate Pusch(Kepler Universitätsklinikum), Anna Sophia Kermanidis(Austrian Breast & Colorectal Cancer Study Group), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group)
Cited by 3
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k